Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.38 |
| ▸ | ATG7 | O95352 | 6/20 | 0.34 |
| ▸ | POLRMT | O00411 | 1/20 | 0.34 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20144205 | 0.85 | DOT1L (0.35) | DOT1LPOLRMT | |
| SCHEMBL23844099 | 0.79 | POLRMT (0.37) | DOT1LPOLRMT | |
| SCHEMBL10154373 | 0.78 | ADRB1 (0.40) | DOT1LPOLRMTSTING1GALR3NR2F2 | |
| SCHEMBL25008844 | 0.78 | ADRB1 (0.40) | DOT1LPOLRMTSTING1GALR3NR2F2 | |
| SCHEMBL24606235 | 0.78 | ADRB1 (0.40) | DOT1LPOLRMTSTING1GALR3NR2F2 | |
| SCHEMBL22972736 | 0.78 | ADRB1 (0.40) | DOT1LPOLRMTSTING1GALR3NR2F2 | |
| SCHEMBL26289321 | 0.78 | POLRMT (0.36) | DOT1LPOLRMT | |
| SCHEMBL26268832 | 0.77 | DOT1L (0.39) | DOT1LATG7POLRMTSTING1 | |
| SCHEMBL25400732 | 0.77 | DOT1L (0.38) | DOT1LATG7POLRMT | |
| SCHEMBL26946941 | 0.77 | DOT1L (0.38) | DOT1LATG7POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | DOT1L 653/4885ATG7 3111/4885POLRMT 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.